You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study

Article metrics

Article menu

Download PDFPDF

Emerging technology, pharmacology and Therapetics
Original research
Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study

 

Online download statistics by month:

Online download statistics by month: December 2019 to March 2024

AbstractFullPdf
Dec 201925619892
Jan 202015714189
Feb 202011210973
Mar 2020898258
Apr 2020616055
May 2020605939
Jun 2020969662
Jul 2020737228
Aug 2020393819
Sep 2020908275
Oct 2020918561
Nov 2020666125
Dec 2020585222
Jan 2021666319
Feb 202112712035
Mar 202114814365
Apr 2021716333
May 2021514230
Jun 2021615744
Jul 2021595520
Aug 2021484611
Sep 2021686526
Oct 2021686745
Nov 2021352830
Dec 2021353117
Jan 2022343319
Feb 2022333724
Mar 2022635827
Apr 2022717223
May 2022575738
Jun 2022464727
Jul 2022212118
Aug 2022282416
Sep 2022211816
Oct 2022313214
Nov 202235275
Dec 2022262318
Jan 2023111010
Feb 202342419
Mar 2023212316
Apr 2023141110
May 2023171312
Jul 2023151512
Aug 202327278
Sep 202323245
Oct 2023909113
Nov 2023414210
Dec 202373719
Jan 2024343411
Feb 2024292914
Mar 2024494845
Total303728431502